Tafenoquine is an 8-aminoquinoline with activity against all human life cycle stages of
Plasmodium vivax, including dormant liver stages–so called hypnozoites. Its long half-life …

Despite declining global malaria incidence, the disease continues to be a threat to people
living in endemic regions. In 2015, an estimated 214 million new malaria cases and 438,000 …

Background Clinical effectiveness of previous regimens to treat Plasmodium vivax infection
have been hampered by compliance. We aimed to assess the dose–response, safety, and …

In our recent paper on the clinical pharmacology of tafenoquine (Watson et al., 2022), we
used all available individual patient pharmacometric data from the tafenoquine pre …

Background Tafenoquine is an investigational 8-aminoquinoline for the prevention of
Plasmodium vivax relapse. Tafenoquine has a long half-life and the potential for more …

Tafenoquine is a newly licensed antimalarial drug for the radical cure of Plasmodium vivax
malaria. The mechanism of action and optimal dosing are uncertain. We pooled individual …

Background Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been
associated with relapse prevention through the clearance of P. vivax parasitemia and …

Abstract Background Treatment of Plasmodium vivax malaria requires the clearing of
asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared …

A single 300 mg dose of tafenoquine, in combination with chloroquine, is currently approved
in several countries for the radical cure (prevention of relapse) of Plasmodium vivax malaria …

Background Tafenoquine, co-administered with chloroquine, is approved for the radical cure
(prevention of relapse) of Plasmodium vivax malaria. In areas of chloroquine resistance …